Tarlatamab is a first-in-class T-cell engager used to treat extensive-stage small cell lung cancer.[L50748] It is a bispecific monoclonal antibody that targets CD3 expressed on the surface of T-cells and delta-like ligand 3 (DLL3), an inhibitory ligand that s…